Literature DB >> 16007185

p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo.

Jesus Perez-Losada1, Di Wu, Reyno DelRosario, Allan Balmain, Jian-Hua Mao.   

Abstract

p53 is one of the most important tumor suppressor genes in human cancer, but the roles of its homologues p63 and p73 in tumor suppression, alone or in collaboration with p53, remains controversial. Both p63 and p73 can be deregulated after DNA damage, and induce cell cycle arrest and apoptosis, but mice carrying inactive alleles of these genes do not develop spontaneous tumors. Since heterozygous loss of p53 confers strong sensitization to radiation-induced lymphoma development, we investigated the possibility that radiation exposure may reveal previously undetected tumor suppressor properties in p63 or p73, alone or in combination with p53. Animals heterozygous for p63 or p73, as well as both double heterozygous p53/p63 or p53/p73 mice, showed no significant differences in tumor latency, spectrum or frequency after gamma-radiation, compared to their control counterparts. Deletions were found near the p63 locus on chromosome 16 in radiation-induced tumors, but these frequently included the knockout allele. No deletions or LOH involving the p73 gene were detected, and expression of both genes was maintained in the tumors. We conclude that p53 homologues do not contribute to p53 tumor suppressor activity in lymphoma development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007185     DOI: 10.1038/sj.onc.1208799

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation.

Authors:  Yingchun Li; Melissa J Peart; Carol Prives
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

2.  A rare association of B cell lymphoma and ectodermal dysplasia presenting with protein-losing enteropathy.

Authors:  Mohamed Yousha Yousuf; Faraz Imran; Andrew Davis
Journal:  BMJ Case Rep       Date:  2009-02-27

3.  Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice.

Authors:  Alice Nemajerova; Oleksi Petrenko; Lorenz Trümper; Gustavo Palacios; Ute M Moll
Journal:  J Clin Invest       Date:  2010-05-17       Impact factor: 14.808

Review 4.  Pathologies associated with the p53 response.

Authors:  Andrei V Gudkov; Elena A Komarova
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-07       Impact factor: 10.005

5.  {Delta}Np73{beta} puts the brakes on DNA repair.

Authors:  Emma Vernersson-Lindahl; Alea A Mills
Journal:  Genes Dev       Date:  2010-03-15       Impact factor: 11.361

6.  p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors.

Authors:  William M Keyes; Hannes Vogel; Maranke I Koster; Xuecui Guo; Yi Qi; Kristin M Petherbridge; Dennis R Roop; Allan Bradley; Alea A Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-19       Impact factor: 11.205

7.  Tracing the protectors path from the germ line to the genome.

Authors:  Daniel Coutandin; Horng Der Ou; Frank Löhr; Volker Dötsch
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-09       Impact factor: 11.205

8.  Impaired repair of cyclobutane pyrimidine dimers in human keratinocytes deficient in p53 and p63.

Authors:  Bridget E Ferguson-Yates; Hongyan Li; Tiffany K Dong; Jennifer L Hsiao; Dennis H Oh
Journal:  Carcinogenesis       Date:  2007-11-04       Impact factor: 4.944

9.  The alpha/beta carboxy-terminal domains of p63 are required for skin and limb development. New insights from the Brdm2 mouse which is not a complete p63 knockout but expresses p63 gamma-like proteins.

Authors:  S Wolff; F Talos; G Palacios; U Beyer; M Dobbelstein; U M Moll
Journal:  Cell Death Differ       Date:  2009-03-20       Impact factor: 15.828

10.  The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73.

Authors:  A Peschiaroli; F Scialpi; F Bernassola; M Pagano; G Melino
Journal:  Oncogene       Date:  2009-07-06       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.